Insight into the molecular mechanism of yeast acetyl-coenzyme A carboxylase mutants F510I, N485G, I69E, E477R, and K73R resistant to soraphen A

Journal of Computer-aided Molecular Design
Jian GaoTonghui Huang

Abstract

Acetyl-coenzyme A carboxylases (ACCs) is the first committed enzyme of fatty acid synthesis pathway. The inhibition of ACC is thought to be beneficial not only for diseases related to metabolism, such as type-2 diabetes, but also for infectious disease like bacterial infection disease. Soraphen A, a potent allosteric inhibitor of BC domain of yeast ACC, exhibit lower binding affinities to several yeast ACC mutants and the corresponding drug resistance mechanisms are still unknown. We report here a theoretical study of binding of soraphen A to wild type and yeast ACC mutants (including F510I, N485G, I69E, E477R, and K73R) via molecular dynamic simulation and molecular mechanics/generalized Born surface area free energy calculations methods. The calculated binding free energies of soraphen A to yeast ACC mutants are weaker than to wild type, which is highly consistent with the experimental results. The mutant F510I weakens the binding affinity of soraphen A to yeast ACC mainly by decreasing the van der Waals contributions, while the weaker binding affinities of Soraphen A to other yeast ACC mutants including N485G, I69E, E477R, and K73R are largely attributed to the decreased net electrostatic (ΔEele + ΔGGB) interactions. Our sim...Continue Reading

References

Oct 24, 2002·Advanced Drug Delivery Reviews·James M Lenhard, William K Gottschalk
Apr 30, 2004·Journal of Computational Chemistry·Junmei WangDavid A Case
Oct 4, 2005·Journal of Computational Chemistry·David A CaseRobert J Woods
Feb 7, 2006·Journal of Molecular Graphics & Modelling·Junmei WangDavid A Case
Jul 5, 2008·Annual Review of Nutrition·David Saggerson
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·J Richard MillerC Kendall Stover
Oct 31, 2009·Bioorganic & Medicinal Chemistry Letters·Cliff C ChengTodd Black
Dec 21, 2011·Applied Microbiology and Biotechnology·S W PolyakG W Booker
Mar 16, 2016·Proceedings of the National Academy of Sciences of the United States of America·Geraldine HarrimanH James Harwood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.